Determination of minimal residual disease in leukaemia patients
Dario Campana,
Dario Campana
Departments of Hematology–Oncology and Pathology, St Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA
Search for more papers by this authorDario Campana,
Dario Campana
Departments of Hematology–Oncology and Pathology, St Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA
Search for more papers by this author D. Campana, MD, PhD, Department of Hematology–Oncology, St Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105–2794, USA. E-mail: [email protected]
References
- Bader, P., Hancock, J., Kreyenberg, H., Goulden, N.J., Niethammer, D., Oakhill, A., Steward, C.G., Handgretinger, R., Beck, J.F. & Klingebiel, T. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668 – 1672.
- Baer, M.R., Stewart, C.C., Dodge, R.K., Leget, G., Sule, N., Mrozek, K., Schiffer, C.A., Powell, B.L., Kolitz, J.E., Moore, J.O., Stone, R.M., Davey, F.R., Carroll, A.J., Larson, R.A. & Bloomfield, C.D. (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood, 97, 3574 – 3580.
- Beishuizen, A., Verhoeven, M.A., Van Wering, E.R., Hahlen, K., Hooijkaas, H. & Van Dongen, J.J. (1994) Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood, 83, 2238 – 2247.
- Beishuizen, A., De Bruijn, M.A., Pongers-Willemse, M.J., Verhoeven, M.A., Van Wering, E.R., Hahlen, K., Breit, T.M., Bruin-Versteeg, S., Hooijkaas, H. & Van Dongen, J.J. (1997) Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia, 11, 2200 – 2207.
- Bielorai, B., Golan, H., Trakhtenbrot, L., Reichart, M., Toren, A., Daniely, M., Zilberstein, Y., Amariglio, N., Rechavi, G. & Kaplinsky, C. (2002) Combined analysis of morphology and fluorescence in situ hybridization in follow-up of minimal residual disease in a child with Philadelphia-positive acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 138, 64 – 68.
- Biondi, A., Valsecchi, M.G., Seriu, T., D'Aniello, E., Willemse, M.J., Fasching, K., Pannunzio, A., Gadner, H., Schrappe, M., Kamps, W.A., Bartram, C.R., Van Dongen, J.J. & Panzer-Grumayer, E.R. (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia, 14, 1939 – 1943.
- Boeckx, N., Willemse, M.J., Szczepanski, T., Van Der Velden, V., Langerak, A.W., Vandekerckhove, P. & Van Dongen, J.J. (2002) Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia, 16, 368 – 375.
- Bradstock, K.F., Janossy, G., Tidman, N., Papageorgiou, E.S., Prentice, H.G., Willoughby, M. & Hoffbrand, A.V. (1981) Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leukemia Research, 5, 301 – 309.
- Brisco, M.J., Sykes, P.J., Hughes, E., Dolman, G., Neoh, S.H., Peng, L.M., Toogood, I. & Morley, A.A. (1997) Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 99, 314 – 319.
- Bruggemann, M., Droese, J., Bolz, I., Luth, P., Pott, C., Von Neuhoff, N., Scheuering, U. & Kneba, M. (2000) Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia, 14, 1419 – 1425.
- Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., Amabile, M., Terragna, C., Ruggeri, D., Piccaluga, P.P., Isidori, A., Malagola, M., Baccarani, M., Tura, S. & Martinelli, G. (2002) Real-time quantitation of minimal residual disease in inv (16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 99, 443 – 449.
- Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. & Goldstone, A.H. (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood, 93, 4131 – 4143.
- Campana, D. & Coustan-Smith, E. (2002) Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 15, 1 – 19.
- Campana, D. & Pui, C.H. (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 85, 1416 – 1434.
- Cave, H., Guidal, C., Rohrlich, P., Delfau, M.H., Broyart, A., Lescoeur, B., Rahimy, C., Fenneteau, O., Monplaisir, N. & D'Auriol, L. (1994) Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood, 83, 1892 – 1902.
- Cave, H., Van Der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer: Childhood Leukemia Cooperative Group. New England Journal of Medicine, 339, 591 – 598 .
- Chen, J.S., Coustan-Smith, E., Suzuki, T., Neale, G.A., Mihara, K., Pui, C.H. & Campana, D. (2001) Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood, 97, 2115 – 2120.
- Chen, X., Pan, Q., Stow, P., Behm, F.G., Goorha, R., Pui, C.H. & Neale, G.A. (2001) Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia, 15, 166 – 170.
- Cilloni, D., Gottardi, E., De Micheli, D., Serra, A., Volpe, G., Messa, F., Rege-Cambrin, G., Guerrasio, A., Divona, M., Lo, C.F. & Saglio, G. (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 16, 2115 – 2121.
- Cimino, G., Elia, L., Rapanotti, M.C., Sprovieri, T., Mancini, M., Cuneo, A., Mecucci, C., Fioritoni, G., Carotenuto, M., Morra, E., Liso, V., Annino, L., Saglio, G., De Rossi, G., Foa, R. & Mandelli, F. (2000) A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood, 95, 96 – 101.
- Ciudad, J., San Miguel, J.F., Lopez-Berges, M.C., Vidriales, B., Valverde, B., Ocqueteau, M., Mateos, G., Caballero, M.D., Hernandez, J., Moro, M.J., Mateos, M.V. & Orfao, A. (1998) Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 3774 – 3781.
- Coustan-Smith, E., Behm, F.G., Sanchez, J., Boyett, J.M., Hancock, M.L., Raimondi, S.C., Rubnitz, J.E., Rivera, G.K., Sandlund, J.T., Pui, C.H. & Campana, D. (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, 351, 550 – 554.
- Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691 – 2696.
- Coustan-Smith, E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002a) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 100, 52 – 58.
- Coustan-Smith, E., Sancho, J., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002b) Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 100, 2399 – 2402.
- Deane, M. & Norton, J.D. (1990) Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias. European Journal of Immunology, 20, 2209 – 2217.
- Diverio, D., Rossi, V., Avvisati, G., De Santis, S., Pistilli, A., Pane, F., Saglio, G., Martinelli, G., Petti, M.C., Santoro, A., Pelicci, P.G., Mandelli, F., Biondi, A. & Lo, C.F. (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. GIMEMA-AIEOP Multicenter ‘AIDA’ trial. Blood, 92, 784 – 789.
- Van Dongen, J.J. & Wolvers-Tettero, I.L. (1991) Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clinica Chimica Acta, 198, 93 – 174.
- Van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., Van Wering, E.R., Ludwig, W.-D., Basso, G., De Bruijn, M.A.C., Cazzaniga, G., Hettinger, K., Van Der Does-van den Berg, A., Hop, W.C.J., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731 – 1738.
- Van Dongen, J.J., Macintyre, E.A., Gabert, J.A., Delabesse, E., Rossi, V., Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., Parreira, A., Gameiro, P., Diaz, M.G., Malec, M., Langerak, A.W., San Miguel, J.F. & Biondi, A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 1901 – 1928.
- Donovan, J.W., Ladetto, M., Zou, G., Neuberg, D., Poor, C., Bowers, D. & Gribben, J.G. (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood, 95, 2651 – 2658.
- Dworzak, M.N., Froschl, G., Printz, D., Mann, G., Potschger, U., Muhlegger, N., Fritsch, G. & Gadner, H. (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 99, 1952 – 1958.
- Eckert, C., Biondi, A., Seeger, K., Cazzaniga, G., Hartmann, R., Beyermann, B., Pogodda, M., Proba, J. & Henze, G. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet, 358, 1239 – 1241.
- Eden, T. (2002) Translation of cure for acute lymphoblastic leukaemia to all children. British Journal of Haematology, 118, 945 – 951.
- Elmaagacli, A.H., Beelen, D.W., Trenschel, R. & Schaefer, U.W. (2000) The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplantation, 25, 91 – 96.
- Estrov, Z., Grunberger, T., Dube, I.D., Wang, Y.P. & Freedman, M.H. (1986) Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. New England Journal of Medicine, 315, 538 – 542.
- Farahat, N., Morilla, A., Owusu-Ankomah, K., Morilla, R., Pinkerton, C.R., Treleaven, J.G., Matutes, E., Powles, R.L. & Catovsky, D. (1998) Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. British Journal of Haematology, 101, 158 – 164.
- Foroni, L., Harrison, C.J., Hoffbrand, A.V. & Potter, M.N. (1999) Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. British Journal of Haematology, 105, 7 – 24.
- Gameiro, P., Moreira, I., Yetgin, S., Papaioannou, M., Potter, M.N., Prentice, H.G., Hoffbrand, A.V. & Foroni, L. (2002) Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia. British Journal of Haematology, 119, 685 – 696.
- Grimwade, D. (1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 106, 591 – 613.
- Gruhn, B., Hongeng, S., Yi, H., Hancock, M.L., Rubnitz, J.E., Neale, G.A. & Kitchingman, G.R. (1998) Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia, 12, 675 – 681.
- Guerrasio, A., Pilatrino, C., De Micheli, D., Cilloni, D., Serra, A., Gottardi, E., Parziale, A., Marmont, F., Diverio, D., Divona, M., Lo Coco, F. & Saglio, G. (2002) Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia, 16, 1176 – 1181.
- De Haas, V., Breunis, W.B., Dee, R., Verhagen, O.J., Kroes, W., Van Wering, E.R., Van Dongen, J.J., Van Den Bergh, H. & Van Der Schoot, C.E. (2002) The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. British Journal of Haematology, 116, 87 – 93.
- Hosen, N., Sonoda, Y., Oji, Y., Kimura, T., Minamiguchi, H., Tamaki, H., Kawakami, M., Asada, M., Kanato, K., Motomura, M., Murakami, M., Fujioka, T., Masuda, T., Kim, E.H., Tsuboi, A., Oka, Y., Soma, T., Ogawa, H. & Sugiyama, H. (2002) Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. British Journal of Haematology, 116, 409 – 420.
- Hunger, S.P., Fall, M.Z., Camitta, B.M., Carroll, A.J., Link, M.P., Lauer, S.J., Mahoney, D.H., Pullen, D.J., Shuster, J.J., Steuber, C.P. & Cleary, M.L. (1998) E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood, 91, 1021 – 1028.
- Janossy, G., Bollum, F.J., Bradstock, K.F. & Ashley, J. (1980) Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood, 56, 430 – 441.
- Kneba, M., Bolz, I., Linke, B. & Hiddemann, W. (1995) Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood, 86, 3930 – 3937.
- Knechtli, C.J.C., Goulden, N.J., Hancock, J.P., Grandage, V.L.G., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998a) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072 – 4079.
- Knechtli, C.J., Goulden, N.J., Hancock, J.P., Harris, E.L., Garland, R.J., Jones, C.G., Grandage, V.L., Rowbottom, A.W., Green, A.F., Clarke, E., Lankester, A.W., Potter, M.N., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998b) Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. British Journal of Haematology, 102, 860 – 871.
- Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 2393 – 2398.
- Krauter, J., Wattjes, M.P., Nagel, S., Heidenreich, O., Krug, U., Kafert, S., Bunjes, D., Bergmann, L., Ganser, A. & Heil, G. (1999) Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. British Journal of Haematology, 107, 80 – 85.
- Laczika, K., Mitterbauer, G., Mitterbauer, M., Knobl, P., Schwarzinger, I., Greinix, H.T., Rabitsch, W., Fonatsch, C., Mannhalter, C., Lechner, K. & Jaeger, U. (2001) Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions. Leukemia and Lymphoma, 42, 923 – 931.
- Li, A., Forestier, E., Rosenquist, R. & Roos, G. (2002) Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye. Experimental Hematology, 30, 1170.
- Liu, Y.J. & Grimwade, D. (2002) Minimal residual disease evaluation in acute myeloid leukaemia. Lancet, 360, 160 – 162.
- Lo Coco, F., Diverio, D., Falini, B., Biondi, A., Nervi, C. & Pelicci, P.G. (1999a) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood, 94, 12 – 22.
- Lo Coco, F., Diverio, D., Avvisati, G., Petti, M.C., Meloni, G., Pogliani, E.M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., Martino, B., Specchia, G. & Mandelli, F. (1999b) Therapy of molecular relapse in acute promyelocytic leukemia. Blood, 94, 2225 – 2229.
- Van Lochem, E.G., Wiegers, Y.M., Van Den Beemd, R., Hahlen, K., Van Dongen, J.J. & Hooijkaas, H. (2000) Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia, 14, 688 – 695.
- Look, A.T. (1997) Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059 – 1064.
- Lorenzana, R., Coustan-Smith, E., Antillon, F., Ribeiro, R.C. & Campana, D. (1999) Simple methods for the rapid exchange of flow cytometric data between remote centers. Leukemia, 14, 336 – 337.
- Lowenberg, B., Downing, J.R. & Burnett, A. (1999) Acute myeloid leukemia. New England Journal of Medicine, 341, 1051 – 1062.
- Lucio, P., Parreira, A., Van Den Beemd, M.W., Van Lochem, E.G., Van Wering, E.R., Baars, E., Porwit-MacDonald, A., Bjorklund, E., Gaipa, G., Biondi, A., Orfao, A., Janossy, G., Van Dongen, J.J. & San Miguel, J.F. (1999) Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia, 13, 419 – 427.
- McKenna, R.W., Washington, L.T., Aquino, D.B., Picker, L.J. & Kroft, S.H. (2001) Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood, 98, 2498 – 2507.
- Malec, M., Bjorklund, E., Soderhall, S., Mazur, J., Sjogren, A.M., Pisa, P., Bjorkholm, M. & Porwit-MacDonald, A. (2001) Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia, 15, 716 – 727.
- Mancini, M., Cedrone, M., Diverio, D., Emanuel, B., Stul, M., Vranckx, H., Brama, M., De Cuia, M.R., Nanni, M., Fazi, F., Mecucci, C., Alimena, G. & Hagemeijer, A. (2000) Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia, 14, 364 – 368.
- Marcucci, G., Caligiuri, M.A., Dohner, H., Archer, K.J., Schlenk, R.F., Dohner, K., Maghraby, E.A. & Bloomfield, C.D. (2001) Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia, 15, 1072 – 1080.
- Martens, A.C., Schultz, F.W. & Hagenbeek, A. (1987) Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood, 70, 1073 – 1078.
- Mathe, G., Schwarzenberg, L., Mery, A.M., Cattan, A., Schneider, M., Amiel, J.L., Schlumberger, J.R., Poisson, J. & Wajcner, G. (1966) Extensive histological and cytological survey of patients with acute leukaemia in ‘complete remission’. British Medical Journal, 5488, 640 – 642.
- Miyamoto, T., Weissman, I.L. & Akashi, K. (2000) AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proceedings of the National Academy of Sciences of the United States of America, 97, 7521 – 7526.
- Morschhauser, F., Cayuela, J.M., Martini, S., Baruchel, A., Rousselot, P., Socie, G., Berthou, P., Jouet, J.P., Straetmans, N., Sigaux, F., Fenaux, P. & Preudhomme, C. (2000) Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. Journal of Clinical Oncology, 18, 788 – 794.
- Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. & Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 1094 – 1104.
- Muller, M.C., Merx, K., Weibetaer, A., Kreil, S., Lahaye, T., Hehlmann, R. & Hochhaus, A. (2002) Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia, 16, 2395 – 2399.
- Munoz, L., Lopez, O., Martino, R., Brunet, S., Bellido, M., Rubiol, E., Sierra, J. & Nomdedeu, J.F. (2000) Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia. Haematologica, 85, 704 – 710.
- Nakao, M., Janssen, J.W., Flohr, T. & Bartram, C.R. (2000) Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Research, 60, 3281 – 3289.
- Neale, G.A., Coustan-Smith, E., Pan, Q., Chen, X., Gruhn, B., Stow, P., Behm, F.G., Pui, C.H. & Campana, D. (1999) Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia, 13, 1221 – 1226.
- Nucifora, G., Larson, R.A. & Rowley, J.D. (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood, 82, 712 – 715.
- Nyvold, C., Madsen, H.O., Ryder, L.P., Seyfarth, J., Svejgaard, A., Clausen, N., Wesenberg, F., Jonsson, O.G., Forestier, E. & Schmiegelow, K. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood, 99, 1253 – 1258.
- Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E.H., Hosen, N., Murakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Nishida, S., Oji, Y., Oka, Y. & Sugiyama, H. (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 101, 1698 – 1704.
- Ouspenskaia, M.V., Johnston, D.A., Roberts, W.M., Estrov, Z. & Zipf, T.F. (1995) Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia, 9, 321 – 328.
-
Pallisgaard, N.,
Clausen, N.,
Schroder, H. &
Hokland, P. (1999) Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript.
Genes Chromosomes and Cancer, 26, 355
–
365.
10.1002/(SICI)1098-2264(199912)26:4<355::AID-GCC10>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- Panzer-Grumayer, E.R., Schneider, M., Panzer, S., Fasching, K. & Gadner, H. (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood, 95, 790 – 794.
- Paolucci, P., Hayward, A.R. & Rapson, N.T. (1979) Pre-B and B cells in children on leukaemia remission maintenance treatment. Clinical and Experimental Immunology, 37, 259 – 266.
- Peham, M., Panzer, S., Fasching, K., Haas, O.A., Fischer, S., Marschalek, R., Gadner, H. & Panzer-Grumayer, E.R. (2002) Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. British Journal of Haematology, 117, 315 – 321.
- Pongers-Willemse, M.J., Verhagen, O.J., Tibbe, G.J., Wijkhuijs, A.J., De Haas, V., Roovers, E., Van Der Schoot, C.E. & Van Dongen, J.J. (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia, 12, 2006 – 2014.
- Pongers-Willemse, M.J., Seriu, T., Stolz, F., D'Aniello, E., Gameiro, P., Pisa, P., Gonzalez, M., Bartram, C.R., Panzer-Grumayer, E.R., Biondi, A., San-Miguel, J.F. & Van Dongen, J.J. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia, 13, 110 – 118.
- Pui, C.H. & Campana, D. (2000) New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 14, 783 – 785.
- Pui, C.H., Campana, D. & Evans, W.E. (2001) Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncology, 2, 597 – 607.
- Radich, J., Gehly, G., Lee, A., Avery, R., Bryant, E., Edmands, S., Gooley, T., Kessler, P., Kirk, J., Ladne, P., Thomas, E.D. & Appelbaum, F.R. (1997) Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood, 89, 2602 – 2609.
- Reichle, A., Rothe, G., Krause, S., Zaiss, M., Ullrich, H., Schmitz, G. & Andreesen, R. (1999) Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia, 13, 1227 – 1234.
- Van Rhee, F., Marks, D.I., Lin, F., Szydlo, R.M., Hochhaus, A., Treleaven, J., Delord, C., Cross, N.C. & Goldman, J.M. (1995) Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia, 9, 329 – 335.
- San Miguel, J.F., Martinez, A., Macedo, A., Vidriales, M.B., Lopez-Berges, C., Gonzalez, M., Caballero, D., Garcia-Marcos, M.A., Ramos, F., Fernandez-Calvo, J., Calmuntia, M.J., Diaz-Mediavilla, J. & Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 2465 – 2470.
- San Miguel, J.F., Vidriales, M.B., Lopez-Berges, C., Diaz-Mediavilla, J., Gutierrez, N., Canizo, C., Ramos, F., Calmuntia, M.J., Perez, J.J., Gonzalez, M. & Orfao, A. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 98, 1746 – 1751.
- Sanchez, J., Serrano, J., Gomez, P., Martinez, F., Martin, C., Madero, L., Herrera, C., Garcia, J.M., Casano, J. & Torres, A. (2002) Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology, 116, 686 – 694.
- Seale, J.R., Varma, S., Swirsky, D.M., Pandolfi, P.P., Goldman, J.M. & Cross, N.C. (1996) Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. British Journal of Haematology, 95, 95 – 101.
- Shih, L.Y., Huang, C.F., Wu, J.H., Lin, T.L., Dunn, P., Wang, P.N., Kuo, M.C., Lai, C.L. & Hsu, H.C. (2002) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood, 100, 2387 – 2392.
- Sievers, E.L., Lange, B.J., Buckley, J.D., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., Shults, K.E., Bernstein, I.D. & Loken, M.R. (1996) Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute, 88, 1483 – 1488.
- Sievers, E.L., Lange, B.J., Alonzo, T.A., Gerbing, R.B., Bernstein, I.D., Smith, F.O., Arceci, R.J., Woods, W.G. & Loken, M.R. (2003) Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood , 101, 3398 – 3406.
- Stirewalt, D.L., Willman, C.L. & Radich, J.P. (2001) Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leukemia Research, 25, 1085 – 1088.
- Sykes, P.J., Neoh, S.H., Brisco, M.J., Hughes, E., Condon, J. & Morley, A.A. (1992) Quantitation of targets for PCR by use of limiting dilution. Biotechniques, 13, 444 – 449.
- Sykes, P.J., Snell, L.E., Brisco, M.J., Neoh, S.H., Hughes, E., Dolman, G., Peng, L.M., Bennett, A., Toogood, I. & Morley, A.A. (1997) The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood. Leukemia, 11, 153 – 158.
- Szczepanski, T., Beishuizen, A., Pongers-Willemse, M.J., Hahlen, K., Van Wering, E.R., Wijkhuijs, A.J., Tibbe, G.J., De Bruijn, M.A. & Van Dongen, J.J. (1999) Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia, 13, 196 – 205.
- Szczepanski, T., Orfao, A., Van Der Velden, V.H., San Miguel, J.F. & Van Dongen, J.J. (2001) Minimal residual disease in leukaemia patients. Lancet Oncology, 2, 409 – 417.
- Szczepanski, T., Willemse, M.J., Brinkhof, B., Van Wering, E.R., Van Der, B.M. & Van Dongen, J.J. (2002) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 99, 2315 – 2323.
- Tobal, K., Newton, J., Macheta, M., Chang, J., Morgenstern, G., Evans, P.A., Morgan, G., Lucas, G.S. & Liu, Y.J. (2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood, 95, 815 – 819.
- Trka, J., Kalinova, M., Hrusak, O., Zuna, J., Krejci, O., Madzo, J., Sedlacek, P., Vavra, V., Michalova, K., Jarosova, M. & Stary, J. (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 16, 1381 – 1389.
- Uckun, F.M., Kersey, J.H., Haake, R., Weisdorf, D., Nesbit, M.E. & Ramsay, N.K. (1993) Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. New England Journal of Medicine, 329, 1296 – 1301.
- Van Wering, E.R., Van Der Linden-Schrever, B.E., Szczepanski, T., Willemse, M.J., Baars, E.A., Wijngaarde-Schmitz, H.M., Kamps, W.A. & Van Dongen, J.J. (2000) Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. British Journal of Haematology, 110, 139 – 146.
- Van Der Velden, V., Willemse, M.J., Van Der Schoot, C.E., Hahlen, K., Van Wering, E.R. & Van Dongen, J.J. (2002a) Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 16, 928 – 936.
- Van Der Velden, V., Jacobs, D.C., Wijkhuijs, A.J., Comans-Bitter, W.M., Willemse, M.J., Hahlen, K., Kamps, W.A., Van Wering, E.R. & Van Dongen, J.J. (2002b) Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 16, 1432 – 1436.
- Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M. & Amadori, S. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 96, 3948 – 3952.
- Verhagen, O.J., Willemse, M.J., Breunis, W.B., Wijkhuijs, A.J., Jacobs, D.C., Joosten, S.A., Van Wering, E.R., Van Dongen, J.J. & Van Der Schoot, C.E. (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 14, 1426 – 1435.
- Willemse, M.J., Seriu, T., Hettinger, K., D'Aniello, E., Hop, W.C., Panzer-Grumayer, E.R., Biondi, A., Schrappe, M., Kamps, W.A., Masera, G., Gadner, H., Riehm, H., Bartram, C.R. & Van Dongen, J.J. (2002) Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood, 99, 4386 – 4393.
- Yokota, S., Hansen-Hagge, T.E., Ludwig, W.D., Reiter, A., Raghavachar, A., Kleihauer, E. & Bartram, C.R. (1991) Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood, 77, 331 – 339.
Citing Literature
